SEARCH

SEARCH BY CITATION

References

  • Abramson, J.S., Hellmann, M., Barnes, J.A., Hammerman, P., Toomey, C., Takvorian, T., Muzikansky, A. & Hochberg, E.P. (2010) Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer, 116, 42834290.
  • Abrey, L.E., DeAngelis, L.M. & Yahalom, J. (1998) Long-term survival in primary CNS lymphoma. Journal of Clinical Oncology, 16, 859863.
  • Abrey, L.E., Moskowitz, C.H., Mason, W.P., Crump, M., Stewart, D., Forsyth, P., Paleologos, N., Correa, D.D., Anderson, N.D., Caron, D., Zelenetz, A., Nimer, S.D. & DeAngelis, L.M. (2003) Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. Journal of Clinical Oncology, 21, 41514156.
  • Abrey, L.E., Batchelor, T.T., Ferreri, A.J., Gospodarowicz, M., Pulczynski, E.J., Zucca, E., Smith, J.R., Korfel, A., Soussain, C., DeAngelis, L.M., Neuwelt, E.A., O'Neill, B.P., Thiel, E., Shenkier, T., Graus, F., van den Bent, M., Seymour, J.F., Poortmans, P., Armitage, J.O. & Cavalli, F. (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. Journal of Clinical Oncology, 23, 50345043.
  • Abrey, L.E., Ben-Porat, L., Panageas, K.S., Yahalom, J., Berkey, B., Curran, W., Schultz, C., Leibel, S., Nelson, D., Mehta, M. & DeAngelis, L.M. (2006) Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. Journal of Clinical Oncology, 24, 57115715.
  • Alvarnas, J.C., Negrin, R.S., Horning, S.J., Hu, W.W., Long, G.D., Schriber, J.R., Stockerl-Goldstein, K., Tierney, K., Wong, R., Blume, K.G. & Chao, N.J. (2000) High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. Biology of Blood and Marrow Transplantation, 6, 352358.
  • Baraniskin, A., Kuhnhenn, J., Schlegel, U., Chan, A., Deckert, M., Gold, R., Maghnouj, A., Zollner, H., Reinacher-Schick, A., Schmiegel, W., Hahn, S.A. & Schroers, R. (2011) Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood, 117, 31403146.
  • Bataille, B., Delwail, V., Menet, E., Vandermarcq, P., Ingrand, P., Wager, M., Guy, G. & Lapierre, F. (2000) Primary intracerebral malignant lymphoma: report of 248 cases. Journal of Neurosurgery, 92, 261266.
  • Batchelor, T. & Loeffler, J.S. (2006) Primary CNS lymphoma. Journal of Clinical Oncology, 24, 12811288.
  • Batchelor, T.T., Kolak, G., Ciordia, R., Foster, C.S. & Henson, J.W. (2003) High-dose methotrexate for intraocular lymphoma. Clinical Cancer Research, 9, 711715.
  • Batchelor, T.T., Grossman, S.A., Mikkelsen, T., Ye, X., Desideri, S. & Lesser, G.J. (2011) Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology, 76, 929930.
  • Berenbom, A., Davila, R.M., Lin, H.S. & Harbour, J.W. (2007) Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy. Eye (London), 21, 11981201.
  • Bernstein, S.H., Unger, J.M., Leblanc, M., Friedberg, J., Miller, T.P. & Fisher, R.I. (2009) Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 – the Southwest Oncology Group. Journal of Clinical Oncology, 27, 114119.
  • Blay, J.Y., Conroy, T., Chevreau, C., Thyss, A., Quesnel, N., Eghbali, H., Bouabdallah, R., Coiffier, B., Wagner, J.P., Le Mevel, A., Dramais-Marcel, D., Baumelou, E., Chauvin, F. & Biron, P. (1998) High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. Journal of Clinical Oncology, 16, 864871.
  • Boehme, V., Zeynalova, S., Kloess, M., Loeffler, M., Kaiser, U., Pfreundschuh, M. & Schmitz, N. (2007) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma–a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Annals of Oncology, 18, 149157.
  • Booman, M., Szuhai, K., Rosenwald, A., Hartmann, E., Kluin-Nelemans, H., de Jong, D., Schuuring, E. & Kluin, P. (2008) Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways. Journal of Pathology, 216, 209217.
  • Boonstra, R., Koning, A., Mastik, M., van den Berg, A. & Poppema, S. (2003) Analysis of chromosomal copy number changes and oncoprotein expression in primary central nervous system lymphomas: frequent loss of chromosome arm 6q. Virchows Archiv, 443, 164169.
  • Braaten, K.M., Betensky, R.A., de Leval, L., Okada, Y., Hochberg, F.H., Louis, D.N., Harris, N.L. & Batchelor, T.T. (2003) BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clinical Cancer Research, 9, 10631069.
  • Braggio, E., McPhail, E.R., Macon, W., Lopes, M.B., Schiff, D., Law, M., Fink, S., Sprau, D., Giannini, C., Dogan, A., Fonseca, R. & O'Neill, B.P. (2011) Primary central nervous system lymphomas: a validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens. Clinical Cancer Research, 17, 42454253.
  • Bromberg, J.E., Doorduijn, J.K., Illerhaus, G., Jahnke, K., Korfel, A., Fischer, L., Fritsch, K., Kuittinen, O., Issa, S., van Montfort, C. & van den Bent, M.J. (2013) Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation - an International Primary Central Nervous System Lymphoma Study Group project. Haematologica, 98, 808813.
  • Cady, F.M., O'Neill, B.P., Law, M.E., Decker, P.A., Kurtz, D.M., Giannini, C., Porter, A.B., Kurtin, P.J., Johnston, P.B., Dogan, A. & Remstein, E.D. (2008) Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. Journal of Clinical Oncology, 26, 48144819.
  • Camilleri-Broet, S., Criniere, E., Broet, P., Delwail, V., Mokhtari, K., Moreau, A., Kujas, M., Raphael, M., Iraqi, W., Sautes-Fridman, C., Colombat, P., Hoang-Xuan, K. & Martin, A. (2006) A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood, 107, 190196.
  • Campo, E., Swerdlow, S.H., Harris, N.L., Pileri, S., Stein, H. & Jaffe, E.S. (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood, 117, 50195032.
  • Chan, C.C., Buggage, R.R. & Nussenblatt, R.B. (2002) Intraocular lymphoma. Current Opinion in Ophthalmology, 13, 411418.
  • Chan, C.C., Rubenstein, J.L., Coupland, S.E., Davis, J.L., Harbour, J.W., Johnston, P.B., Cassoux, N., Touitou, V., Smith, J.R., Batchelor, T.T. & Pulido, J.S. (2011) Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist, 16, 15891599.
  • Cingolani, A., Gastaldi, R., Fassone, L., Pierconti, F., Giancola, M.L., Martini, M., De Luca, A., Ammassari, A., Mazzone, C., Pescarmona, E., Gaidano, G., Larocca, L.M. & Antinori, A. (2000) Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas. Journal of Clinical Oncology, 18, 33253330.
  • Correa, D.D., Rocco-Donovan, M., DeAngelis, L.M., Dolgoff-Kaspar, R., Iwamoto, F., Yahalom, J. & Abrey, L.E. (2009) Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. Journal of Neurooncology, 91, 315321.
  • Correa, D.D., Shi, W., Abrey, L.E., Deangelis, L.M., Omuro, A.M., Deutsch, M.B. & Thaler, H.T. (2012) Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro-Oncology, 14, 101108.
  • Cote, G.M., Hochberg, E.P., Muzikansky, A., Hochberg, F.H., Drappatz, J., McAfee, S.L., Batchelor, T.T., LaCasce, A.S., Fisher, D.C., Abramson, J.S., Armand, P. & Chen, Y.B. (2012) Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma. Biology of Blood and Marrow Transplantation, 18, 7683.
  • Courts, C., Montesinos-Rongen, M., Brunn, A., Bug, S., Siemer, D., Hans, V., Blumcke, I., Klapper, W., Schaller, C., Wiestler, O.D., Kuppers, R., Siebert, R. & Deckert, M. (2008) Recurrent inactivation of the PRDM1 gene in primary central nervous system lymphoma. Journal of Neuropathology and Experimental Neurology, 67, 720727.
  • Damon, L., Damon, L.E., Gaensler, K., Kaplan, L., Martin, T. 3rd, Rubenstein, J. & Linker, C. (2008) Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma. Bone Marrow Transplantation, 42, 649657.
  • Damon, L.E., Johnson, J.L., Niedzwiecki, D., Cheson, B.D., Hurd, D.D., Bartlett, N.L., Lacasce, A.S., Blum, K.A., Byrd, J.C., Kelly, M., Stock, W., Linker, C.A. & Canellos, G.P. (2009) Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. Journal of Clinical Oncology, 27, 61016108.
  • DeAngelis, L.M., Yahalom, J., Heinemann, M.H., Cirrincione, C., Thaler, H.T. & Krol, G. (1990) Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy. Neurology, 40, 8086.
  • DeAngelis, L.M., Yahalom, J., Thaler, H.T. & Kher, U. (1992) Combined modality therapy for primary CNS lymphoma. Journal of Clinical Oncology, 10, 635643.
  • DeAngelis, L.M., Seiferheld, W., Schold, S.C., Fisher, B. & Schultz, C.J. (2002) Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. Journal of Clinical Oncology, 20, 46434648.
  • Elstrom, R.L., Andreadis, C., Aqui, N.A., Ahya, V.N., Bloom, R.D., Brozena, S.C., Olthoff, K.M., Schuster, S.J., Nasta, S.D., Stadtmauer, E.A. & Tsai, D.E. (2006) Treatment of PTLD with rituximab or chemotherapy. American Journal of Transplantation, 6, 569576.
  • Ervin, T. & Canellos, G.P. (1980) Successful treatment of recurrent primary central nervous system lymphoma with high-dose methotrexate. Cancer, 45, 15561557.
  • Falzetti, F., Di Ianni, M., Ballanti, S., Iodice, G., Reale, A., Minelli, O., Serio, G., Martelli, M.F., Dammacco, F., Vacca, A. & Ria, R. (2012) High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma. Clinical and Experimental Medicine, 12, 165171.
  • Ferreri, A.J., Reni, M., Zoldan, M.C., Terreni, M.R. & Villa, E. (1996) Importance of complete staging in non-Hodgkin's lymphoma presenting as a cerebral mass lesion. Cancer, 77, 827833.
  • Ferreri, A.J., Blay, J.Y., Reni, M., Pasini, F., Spina, M., Ambrosetti, A., Calderoni, A., Rossi, A., Vavassori, V., Conconi, A., Devizzi, L., Berger, F., Ponzoni, M., Borisch, B., Tinguely, M., Cerati, M., Milani, M., Orvieto, E., Sanchez, J., Chevreau, C., Dell'Oro, S., Zucca, E. & Cavalli, F. (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. Journal of Clinical Oncology, 21, 266272.
  • Ferreri, A.J., Reni, M., Foppoli, M., Martelli, M., Pangalis, G.A., Frezzato, M., Cabras, M.G., Fabbri, A., Corazzelli, G., Ilariucci, F., Rossi, G., Soffietti, R., Stelitano, C., Vallisa, D., Zaja, F., Zoppegno, L., Aondio, G.M., Avvisati, G., Balzarotti, M., Brandes, A.A., Fajardo, J., Gomez, H., Guarini, A., Pinotti, G., Rigacci, L., Uhlmann, C., Picozzi, P., Vezzulli, P., Ponzoni, M., Zucca, E., Caligaris-Cappio, F. & Cavalli, F. (2009) High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet, 374, 15121520.
  • Feugier, P., Virion, J.M., Tilly, H., Haioun, C., Marit, G., Macro, M., Bordessoule, D., Recher, C., Blanc, M., Molina, T., Lederlin, P. & Coiffier, B. (2004) Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Annals of Oncology, 15, 129133.
  • Fine, H.A. & Mayer, R.J. (1993) Primary central nervous system lymphoma. Annals of Internal Medicine, 119, 10931104.
  • Fischer, L., Martus, P., Weller, M., Klasen, H.A., Rohden, B., Roth, A., Storek, B., Hummel, M., Nagele, T., Thiel, E. & Korfel, A. (2008) Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients. Neurology, 71, 11021108.
  • Fischer, L., Korfel, A., Pfeiffer, S., Kiewe, P., Volk, H.D., Cakiroglu, H., Widmann, T. & Thiel, E. (2009) CXCL13 and CXCL12 in central nervous system lymphoma patients. Clinical Cancer Research, 15, 59685973.
  • Fischer, L., Hummel, M., Korfel, A., Lenze, D., Joehrens, K. & Thiel, E. (2011) Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas. Neuro-Oncology, 13, 10901098.
  • Glantz, M.J., Cole, B.F., Recht, L., Akerley, W., Mills, P., Saris, S., Hochberg, F., Calabresi, P. & Egorin, M.J. (1998) High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? Journal of Clinical Oncology, 16, 15611567.
  • Glass, J., Gruber, M.L., Cher, L. & Hochberg, F.H. (1994) Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. Journal of Neurosurgery, 81, 188195.
  • van de Glind, G., de Graaf, S., Klein, C., Cornelissen, M., Maecker, B. & Loeffen, J. (2008) Intrathecal rituximab treatment for pediatric post-transplant lymphoproliferative disorder of the central nervous system. Pediatric Blood & Cancer, 50, 886888.
  • Gonzalez-Aguilar, A., Idbaih, A., Boisselier, B., Habbita, N., Rossetto, M., Laurenge, A., Bruno, A., Jouvet, A., Polivka, M., Adam, C., Figarella-Branger, D., Miquel, C., Vital, A., Ghesquieres, H., Gressin, R., Delwail, V., Taillandier, L., Chinot, O., Soubeyran, P., Gyan, E., Choquet, S., Houillier, C., Soussain, C., Tanguy, M.L., Marie, Y., Mokhtari, K. & Hoang-Xuan, K. (2012) Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clinical Cancer Research, 18, 52035211.
  • Green, J.M. (2012) Glucarpidase to combat toxic levels of methotrexate in patients. Therapeutics and Clinical Risk Management, 8, 403413.
  • Harada, K., Nishizaki, T., Kubota, H., Suzuki, M. & Sasaki, K. (2001) Distinct primary central nervous system lymphoma defined by comparative genomic hybridization and laser scanning cytometry. Cancer Genetics and Cytogenetics, 125, 147150.
  • Hochberg, F.H. & Miller, D.C. (1988) Primary central nervous system lymphoma. Journal of Neurosurgery, 68, 835853.
  • Illerhaus, G., Muller, F., Feuerhake, F., Schafer, A.O., Ostertag, C. & Finke, J. (2008) High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica, 93, 147148.
  • Itty, S. & Pulido, J.S. (2009) Rituximab for intraocular lymphoma. Retina, 29, 129132.
  • Jacomet, C., Girard, P.M., Lebrette, M.G., Farese, V.L., Monfort, L. & Rozenbaum, W. (1997) Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS. Acquired Immune Deficiency Syndrome, 11, 17251730.
  • Jahnke, K., Thiel, E., Bechrakis, N.E., Willerding, G., Kraemer, D.F., Fischer, L. & Korfel, A. (2009) Ifosfamide or trofosfamide in patients with intraocular lymphoma. Journal of Neurooncology, 93, 213217.
  • Jordanova, E.S., Riemersma, S.A., Philippo, K., Giphart-Gassler, M., Schuuring, E. & Kluin, P.M. (2002) Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B-cell lymphomas of the testis and the central nervous system. Genes, Chromosomes & Cancer, 35, 3848.
  • Josephson, S.A., Papanastassiou, A.M., Berger, M.S., Barbaro, N.M., McDermott, M.W., Hilton, J.F., Miller, B.L. & Geschwind, M.D. (2007) The diagnostic utility of brain biopsy procedures in patients with rapidly deteriorating neurological conditions or dementia. Journal of Neurosurgery, 106, 7275.
  • Kadoch, C., Li, J., Wong, V.S., Chen, L., Cha, S., Munster, P.N., Lowell, C.A., Shuman, M.A. & Rubenstein, J.L. (2013) Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma. Clinical Cancer Research, 20, 10291041.
  • Khan, R.B., Shi, W., Thaler, H.T., DeAngelis, L.M. & Abrey, L.E. (2002) Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? Journal of Neurooncology, 58, 175178.
  • Kitzmann, A.S., Pulido, J.S., Mohney, B.G., Baratz, K.H., Grube, T., Marler, R.J., Donaldson, M.J., O'Neill, B.P., Johnston, P.B., Johnson, K.M., Dixon, L.E., Salomao, D.R. & Cameron, J.D. (2007) Intraocular use of rituximab. Eye (London), 21, 15241527.
  • Korfel, A., Elter, T., Thiel, E., Hanel, M., Mohle, R., Schroers, R., Reiser, M., Dreyling, M., Eucker, J., Scholz, C., Metzner, B., Roth, A., Birkmann, J., Schlegel, U., Martus, P., Illerhaus, G. & Fischer, L. (2013) Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica, 98, 364370.
  • Kuker, W., Nagele, T., Korfel, A., Heckl, S., Thiel, E., Bamberg, M., Weller, M. & Herrlinger, U. (2005) Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. Journal of Neurooncology, 72, 169177.
  • Lai, R., Rosenblum, M.K. & DeAngelis, L.M. (2002) Primary CNS lymphoma: a whole-brain disease? Neurology, 59, 15571562.
  • Linker, C.A., Owzar, K., Powell, B., Hurd, D., Damon, L.E., Archer, L.E. & Larson, R.A. (2009) Auto-SCT for AML in second remission: CALGB study 9620. Bone Marrow Transplantation, 44, 353359.
  • Mohile, N.A., Deangelis, L.M. & Abrey, L.E. (2008) The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro-Oncology, 10, 223228.
  • Montesinos-Rongen, M., Schmitz, R., Brunn, A., Gesk, S., Richter, J., Hong, K., Wiestler, O.D., Siebert, R., Kuppers, R. & Deckert, M. (2010) Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma. Acta Neuropathologica, 120, 529535.
  • Montesinos-Rongen, M., Godlewska, E., Brunn, A., Wiestler, O.D., Siebert, R. & Deckert, M. (2011) Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. Acta Neuropathologica, 122, 791792.
  • Montesinos-Rongen, M., Schafer, E., Siebert, R. & Deckert, M. (2012) Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma. Acta Neuropathologica, 124, 905906.
  • Morris, P.G., Correa, D.D., Yahalom, J., Raizer, J.J., Schiff, D., Grant, B., Grimm, S., Lai, R.K., Reiner, A.S., Panageas, K., Karimi, S., Curry, R., Shah, G., Abrey, L.E., DeAngelis, L.M. & Omuro, A. (2013) Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. Journal of Clinical Oncology, 31, 39713979.
  • Muniz, C., Martin-Martin, L., Lopez, A., Sanchez-Gonzalez, B., Salar, A., Almeida, J., Sancho, J.M., Ribera, J.M., Heras, C., Penalver, F., Gomez, M., Gonzalez-Barca, E., Alonso, N., Navarro, B., Olave, T., Sala, F., Conde, E., Marquez, J.A., Cabezudo, E., Cladera, A., Garcia-Malo, M., Caballero, M.D. & Orfao, A. (2014) Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome. Blood, 123, 18641869.
  • Nakamura, M., Kishi, M., Sakaki, T., Hashimoto, H., Nakase, H., Shimada, K., Ishida, E. & Konishi, N. (2003) Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas. Cancer Research, 63, 737741.
  • Nelson, D.F., Martz, K.L., Bonner, H., Nelson, J.S., Newall, J., Kerman, H.D., Thomson, J.W. & Murray, K.J. (1992) Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. International Journal of Radiation Oncology Biology Physics, 23, 917.
  • Ngo, V.N., Young, R.M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K.H., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., Shaffer, A.L., Romesser, P., Wright, G., Powell, J., Rosenwald, A., Muller-Hermelink, H.K., Ott, G., Gascoyne, R.D., Connors, J.M., Rimsza, L.M., Campo, E., Jaffe, E.S., Delabie, J., Smeland, E.B., Fisher, R.I., Braziel, R.M., Tubbs, R.R., Cook, J.R., Weisenburger, D.D., Chan, W.C. & Staudt, L.M. (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature, 470, 115119.
  • Norden, A.D., Drappatz, J., Wen, P.Y. & Claus, E.B. (2011) Survival among patients with primary central nervous system lymphoma, 1973-2004. Journal of Neurooncology, 101, 487493.
  • Osoba, D., Brada, M., Yung, W.K. & Prados, M. (2000a) Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. Journal of Clinical Oncology, 18, 14811491.
  • Osoba, D., Brada, M., Yung, W.K. & Prados, M.D. (2000b) Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. European Journal of Cancer, 36, 17881795.
  • Ott, R.J., Brada, M., Flower, M.A., Babich, J.W., Cherry, S.R. & Deehan, B.J. (1991) Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma. European Journal of Cancer, 27, 13561361.
  • Pirotte, B., Levivier, M., Goldman, S., Brucher, J.M., Brotchi, J. & Hildebrand, J. (1997) Glucocorticoid-induced long-term remission in primary cerebral lymphoma: case report and review of the literature. Journal of Neurooncology, 32, 6369.
  • Ponzoni, M., Berger, F., Chassagne-Clement, C., Tinguely, M., Jouvet, A., Ferreri, A.J., Dell'Oro, S., Terreni, M.R., Doglioni, C., Weis, J., Cerati, M., Milani, M., Iuzzolino, P., Motta, T., Carbone, A., Pedrinis, E., Sanchez, J., Blay, J.Y., Reni, M., Conconi, A., Bertoni, F., Zucca, E., Cavalli, F. & Borisch, B. (2007) Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas. British Journal of Haematology, 138, 316323.
  • Ponzoni, M., Issa, S., Batchelor, T.T. & Rubenstein, J.L. (2013) Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma. Annals of Oncology, 25, 316322.
  • Porter, A.B., Giannini, C., Kaufmann, T., Lucchinetti, C.F., Wu, W., Decker, P.A., Atkinson, J.L. & O'Neill, B.P. (2008) Primary central nervous system lymphoma can be histologically diagnosed after previous corticosteroid use: a pilot study to determine whether corticosteroids prevent the diagnosis of primary central nervous system lymphoma. Annals of Neurology, 63, 662667.
  • Quijano, S., Lopez, A., Manuel Sancho, J., Panizo, C., Deben, G., Castilla, C., Antonio Garcia-Vela, J., Salar, A., Alonso-Vence, N., Gonzalez-Barca, E., Penalver, F.J., Plaza-Villa, J., Morado, M., Garcia-Marco, J., Arias, J., Briones, J., Ferrer, S., Capote, J., Nicolas, C. & Orfao, A. (2009) Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. Journal of Clinical Oncology, 27, 14621469.
  • Raizer, J.J., Rademaker, A., Evens, A.M., Rice, L., Schwartz, M., Chandler, J.P., Getch, C.C., Tellez, C. & Grimm, S.A. (2012) Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. Cancer, 118, 37433748.
  • Relling, M.V., Mahmoud, H.H., Pui, C.H., Sandlund, J.T., Rivera, G.K., Ribeiro, R.C., Crist, W.M. & Evans, W.E. (1996) Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. Journal of Clinical Oncology, 14, 399404.
  • Reni, M., Ferreri, A.J., Landoni, C. & Villa, E. (2000) Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. Journal of the National Cancer Institute, 92, 575576.
  • Reni, M., Zaja, F., Mason, W., Perry, J., Mazza, E., Spina, M., Bordonaro, R., Ilariucci, F., Faedi, M., Corazzelli, G., Manno, P., Franceschi, E., Pace, A., Candela, M., Abbadessa, A., Stelitano, C., Latte, G. & Ferreri, A.J. (2007) Temozolomide as salvage treatment in primary brain lymphomas. British Journal of Cancer, 96, 864867.
  • Roy, S., Josephson, S.A., Fridlyand, J., Karch, J., Kadoch, C., Karrim, J., Damon, L., Treseler, P., Kunwar, S., Shuman, M.A., Jones, T., Becker, C.H., Schulman, H. & Rubenstein, J.L. (2008) Protein biomarker identification in the CSF of patients with CNS lymphoma. Journal of Clinical Oncology, 26, 96105.
  • Rubenstein, J.L., Combs, D., Rosenberg, J., Levy, A., McDermott, M., Damon, L., Ignoffo, R., Aldape, K., Shen, A., Lee, D., Grillo-Lopez, A. & Shuman, M.A. (2003) Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood, 101, 466468.
  • Rubenstein, J.L., Treseler, P. & O'Brien, J.M. (2005) Pathology and genetics of primary central nervous system and intraocular lymphoma. Hematology/Oncology Clinics of North America, 19, 705717, vii.
  • Rubenstein, J.L., Fridlyand, J., Shen, A., Aldape, K., Ginzinger, D., Batchelor, T., Treseler, P., Berger, M., McDermott, M., Prados, M., Karch, J., Okada, C., Hyun, W., Parikh, S., Haqq, C. & Shuman, M. (2006) Gene expression and angiotropism in primary CNS lymphoma. Blood, 107, 37163723.
  • Rubenstein, J.L., Fridlyand, J., Abrey, L., Shen, A., Karch, J., Wang, E., Issa, S., Damon, L., Prados, M., McDermott, M., O'Brien, J., Haqq, C. & Shuman, M. (2007) Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. Journal of Clinical Oncology, 25, 13501356.
  • Rubenstein, J.L., Gupta, N.K., Mannis, G.N., Lamarre, A.K. & Treseler, P. (2013a) How I treat CNS lymphomas. Blood, 122, 23182330.
  • Rubenstein, J.L., Hsi, E.D., Johnson, J.L., Jung, S.H., Nakashima, M.O., Grant, B., Cheson, B.D. & Kaplan, L.D. (2013b) Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). Journal of Clinical Oncology, 31, 30613068.
  • Rubenstein, J.L., Wong, V.S., Kadoch, C., Gao, H.X., Barajas, R., Chen, L., Josephson, S.A., Scott, B., Douglas, V., Maiti, M., Kaplan, L.D., Treseler, P.A., Cha, S., Hwang, J.H., Cinque, P., Cyster, J.G. & Lowell, C. (2013c) CXCL13 plus interleukin-10 are highly specific for the diagnosis of CNS lymphoma. Blood, 121, 47404748.
  • Rubenstein, J.L., Li, J., Chen, L., Advani, R., Drappatz, J., Gerstner, E., Batchelor, T., Krouwer, H., Hwang, J., Auerback, G., Kadoch, C., Lowell, C., Munster, P., Cha, S., Shuman, M.A. & Damon, L.E. (2013d) Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood, 121, 745751.
  • Sasayama, T., Nakamizo, S., Nishihara, M., Kawamura, A., Tanaka, H., Mizukawa, K., Miyake, S., Taniguchi, M., Hosoda, K. & Kohmura, E. (2012) Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL). Neuro-Oncology, 14, 368380.
  • Schabet, M. (1999) Epidemiology of primary CNS lymphoma. Journal of Neurooncology, 43, 199201.
  • Schaich, M., Rollig, C., Soucek, S., Kramer, M., Thiede, C., Mohr, B., Oelschlaegel, U., Schmitz, N., Stuhlmann, R., Wandt, H., Schafer-Eckart, K., Aulitzky, W., Kaufmann, M., Bodenstein, H., Tischler, J., Ho, A., Kramer, A., Bornhauser, M., Schetelig, J. & Ehninger, G. (2011) Cytarabine dose of 36 g/m(2) compared with 12 g/m(2) within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. Journal of Clinical Oncology, 29, 26962702.
  • Schaich, M., Parmentier, S., Kramer, M., Illmer, T., Stolzel, F., Rollig, C., Thiede, C., Hanel, M., Schafer-Eckart, K., Aulitzky, W., Einsele, H., Ho, A.D., Serve, H., Berdel, W.E., Mayer, J., Schmitz, N., Krause, S.W., Neubauer, A., Baldus, C.D., Schetelig, J., Bornhauser, M. & Ehninger, G. (2013) High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. Journal of Clinical Oncology, 31, 20942102.
  • Schwindt, H., Vater, I., Kreuz, M., Montesinos-Rongen, M., Brunn, A., Richter, J., Gesk, S., Ammerpohl, O., Wiestler, O.D., Hasenclever, D., Deckert, M. & Siebert, R. (2009) Chromosomal imbalances and partial uniparental disomies in primary central nervous system lymphoma. Leukemia, 23, 18751884.
  • Shah, G.D., Yahalom, J., Correa, D.D., Lai, R.K., Raizer, J.J., Schiff, D., LaRocca, R., Grant, B., DeAngelis, L.M. & Abrey, L.E. (2007) Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. Journal of Clinical Oncology, 25, 47304735.
  • Shenkier, T.N., Blay, J.Y., O'Neill, B.P., Poortmans, P., Thiel, E., Jahnke, K., Abrey, L.E., Neuwelt, E., Tsang, R., Batchelor, T., Harris, N., Ferreri, A.J., Ponzoni, M., O'Brien, P., Rubenstein, J. & Connors, J.M. (2005) Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. Journal of Clinical Oncology, 23, 22332239.
  • Skarin, A.T., Zuckerman, K.S., Pitman, S.W., Rosenthal, D.S., Moloney, W., Frei, E. 3rd & Canellos, G.P. (1977) High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. Blood, 50, 10391047.
  • Smith, J.R., Braziel, R.M., Paoletti, S., Lipp, M., Uguccioni, M. & Rosenbaum, J.T. (2003) Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood, 101, 815821.
  • Smith, J.R., Falkenhagen, K.M., Coupland, S.E., Chipps, T.J., Rosenbaum, J.T. & Braziel, R.M. (2007) Malignant B cells from patients with primary central nervous system lymphoma express stromal cell-derived factor-1. American Journal of Clinical Pathology, 127, 633641.
  • Soussain, C., Suzan, F., Hoang-Xuan, K., Cassoux, N., Levy, V., Azar, N., Belanger, C., Achour, E., Ribrag, V., Gerber, S., Delattre, J.Y. & Leblond, V. (2001) Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. Journal of Clinical Oncology, 19, 742749.
  • Soussain, C., Hoang-Xuan, K., Taillandier, L., Fourme, E., Choquet, S., Witz, F., Casasnovas, O., Dupriez, B., Souleau, B., Taksin, A.L., Gisselbrecht, C., Jaccard, A., Omuro, A., Sanson, M., Janvier, M., Kolb, B., Zini, J.M. & Leblond, V. (2008) Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. Journal of Clinical Oncology, 26, 25122518.
  • Stefanovic, A., Davis, J., Murray, T., Markoe, A. & Lossos, I.S. (2010) Treatment of isolated primary intraocular lymphoma with high-dose methotrexate-based chemotherapy and binocular radiation therapy: a single-institution experience. British Journal of Haematology, 151, 103106.
  • Sun, A., Bae, K., Gore, E.M., Movsas, B., Wong, S.J., Meyers, C.A., Bonner, J.A., Schild, S.E., Gaspar, L.E., Bogart, J.A., Werner-Wasik, M. & Choy, H. (2011) Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. Journal of Clinical Oncology, 29, 279286.
  • Sung, C.O., Kim, S.C., Karnan, S., Karube, K., Shin, H.J., Nam, D.H., Suh, Y.L., Kim, S.H., Kim, J.Y., Kim, S.J., Kim, W.S., Seto, M. & Ko, Y.H. (2011) Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma. Blood, 117, 12911300.
  • Tai, W.M., Chung, J., Tang, P.L., Koo, Y.X., Hou, X., Tay, K.W., Quek, R., Tao, M. & Lim, S.T. (2011) Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Annals of Hematology, 90, 809818.
  • Thiel, E., Korfel, A., Martus, P., Kanz, L., Griesinger, F., Rauch, M., Roth, A., Hertenstein, B., von Toll, T., Hundsberger, T., Mergenthaler, H.G., Leithauser, M., Birnbaum, T., Fischer, L., Jahnke, K., Herrlinger, U., Plasswilm, L., Nagele, T., Pietsch, T., Bamberg, M. & Weller, M. (2010) High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. The Lancet Oncology, 11, 10361047.
  • Tu, P.H., Giannini, C., Judkins, A.R., Schwalb, J.M., Burack, R., O'Neill, B.P., Yachnis, A.T., Burger, P.C., Scheithauer, B.W. & Perry, A. (2005) Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: a primary low-grade CNS lymphoma that mimics meningioma. Journal of Clinical Oncology, 23, 57185727.
  • Tun, H.W., Personett, D., Baskerville, K.A., Menke, D.M., Jaeckle, K.A., Kreinest, P., Edenfield, B., Zubair, A.C., O'Neill, B.P., Lai, W.R., Park, P.J. & McKinney, M. (2008) Pathway analysis of primary central nervous system lymphoma. Blood, 111, 32003210.
  • Villano, J.L., Koshy, M., Shaikh, H., Dolecek, T.A. & McCarthy, B.J. (2011) Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. British Journal of Cancer, 105, 14141418.
  • Weller, M., Martus, P., Roth, P., Thiel, E. & Korfel, A. (2012) Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro-Oncology, 14, 14811484.
  • Wieduwilt, M.J., Valles, F., Issa, S., Behler, C.M., Hwang, J., McDermott, M., Treseler, P., O'Brien, J., Shuman, M.A., Cha, S., Damon, L.E. & Rubenstein, J.L. (2012) Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clinical Cancer Research, 18, 11461155.
  • Wilson, W.H., Bryant, G., Bates, S., Fojo, A., Wittes, R.E., Steinberg, S.M., Kohler, D.R., Jaffe, E.S., Herdt, J., Cheson, B.D. & Chabner, B.A. (1993) EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. Journal of Clinical Oncology, 11, 15731582.
  • Wilson, W.H., Dunleavy, K., Pittaluga, S., Hegde, U., Grant, N., Steinberg, S.M., Raffeld, M., Gutierrez, M., Chabner, B.A., Staudt, L., Jaffe, E.S. & Janik, J.E. (2008) Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. Journal of Clinical Oncology, 26, 27172724.
  • Wong, E.T., Tishler, R., Barron, L. & Wu, J.K. (2004) Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer, 101, 139145.
  • Yamamoto, W., Tomita, N., Watanabe, R., Hattori, Y., Nakajima, Y., Hyo, R., Hashimoto, C., Motomura, S. & Ishigatsubo, Y. (2010) Central nervous system involvement in diffuse large B-cell lymphoma. European Journal of Haematology, 85, 610.